Pain Therapeutics Inc. (NASDAQ:PTIE) kept active in under and overvalue discussion, PTIE holds price to book ratio of 2.66 that presents much better indicator to find market price of a share price over its book value of equity for investment valuation. Pain Therapeutics, Inc. (Nasdaq:PTIE) reported recently that it has attained a Complete Response Letter (CRL) from the U.S. Fda on the resubmission of its new drug application (NDA) for REMOXY ER (oxycodone capsules CII). The CRL informs that REMOXY ER cannot be agreed in its present form and specifies additional actions and data that are needed for drug authorization .
The CRL focuses on the abuse-deterrent properties of REMOXY ER and proposed drug labeling. The CRL makes no mention of clinical safety, drug efficacy, manufacturing, stability, bioequivalence or any other issues from a previous Complete Response Letter.
Pain Therapeutics is evaluating the CRL and plan additional discussions with the FDA. The CRL specifies additional actions that are needed in order to obtain authorization of REMOXY ER with label claims against three routes of abuse (i.e., injection, inhalation and snorting). These actions may take about a year to conduct and may cost about $5MM, pending discussions with the FDA and outside clinical/regulatory consultants.
The firm has price volatility of 17.26% for a week and 10.63% for a month. Its beta stands at 1.47 times. Narrow down four to firm performance, its weekly performance was -46.59% and monthly performance was -43.64%.
Agilent Technologies, Inc. (NYSE:A) runs in leading trade, it are easing down -0.09% to traded at $46.57. A attains analyst recommendation of 2.00 on scale of 1-5 with week’s performance of 3.60%. Agilent Technologies Inc. (NYSE:A) recently reported the EU launch of a new CE-IVD labeled IQFISH lung cancer panel for automated analysis on Dako Omnis. The new panel enables routine pathology laboratories to easily integrate fast, high-quality FISH into their IHC workflow.
“We are excited about the upcoming probe launches for Dako Omnis,” stated Jacob Thaysen, president of Agilent’s Diagnostics and Genomics Group. “Agilent is committed to improving the speed and accuracy of patient-sample processing and the quality of test performance. We know that these factors greatly affect treatment decisions and patient outcome.”
To find out the technical position of A, it holds price to book ratio of 3.49 that unearth high-growth companies selling at low-growth prices, but it requires appropriate measurement approach. It has forward price to earnings ratio of 21.26, and price to earnings ratio calculated as 31.96. The price to earnings growth ration calculated as 2.99. A is presenting price to cash flow of 6.87.
EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 90.50%, and looking further price to next year’s EPS is 14.65%. While take a short look on price to sales ratio, that was 3.66 and price to earning ration of 31.96 attracting passive investors.